D J Wallace

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Management of lupus erythematosus: recent insights
    Daniel J Wallace
    Cedars Sinai UCLA School of Medicine, Los Angeles, California 90048, USA
    Curr Opin Rheumatol 14:212-9. 2002
  2. ncbi request reprint Fibromyalgia: the gastrointestinal link
    Daniel J Wallace
    Cedars Sinai UCLA School of Medicine, 8737 Beverly Blvd, Suite 203, Los Angeles, CA 90048, USA
    Curr Pain Headache Rep 8:364-8. 2004
  3. ncbi request reprint Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia
    Daniel J Wallace
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Semin Arthritis Rheum 37:256-9. 2008
  4. pmc Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    Daniel J Wallace
    David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, UCLA, Los Angeles, California, USA
    Ann Rheum Dis 73:183-90. 2014
  5. pmc New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus
    Fang Fang Wang
    Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, 145 Middle Shan Dong Road, Shanghai 200001, China
    Arthritis Res Ther 14:R103. 2012
  6. doi request reprint Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
    Daniel J Wallace
    Cedars Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA
    Rheumatology (Oxford) 52:1313-22. 2013
  7. doi request reprint Epratuzumab for systemic lupus erythematosus
    D J Wallace
    Cedars Sinai David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 22:400-5. 2013
  8. doi request reprint Ten developments in the use of biologicals for systemic lupus erythematosus
    Daniel J Wallace
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Curr Rheumatol Rep 15:337. 2013
  9. doi request reprint Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
    D J Wallace
    Cedars Sinai Medical Center David Geffen School of Medicine at UCLA, 8737 Beverly Blvd, W Hollywood, CA 90048, USA
    Lupus 22:144-54. 2013
  10. doi request reprint New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
    Daniel J Wallace
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Becker B 131, Los Angeles, CA 90048, USA
    Nat Rev Rheumatol 8:522-33. 2012

Detail Information

Publications77

  1. ncbi request reprint Management of lupus erythematosus: recent insights
    Daniel J Wallace
    Cedars Sinai UCLA School of Medicine, Los Angeles, California 90048, USA
    Curr Opin Rheumatol 14:212-9. 2002
    ..Twelve biologic agents have been studied in lupus since 1999, with only LJP-394 showing clear-cut, convincing efficacy...
  2. ncbi request reprint Fibromyalgia: the gastrointestinal link
    Daniel J Wallace
    Cedars Sinai UCLA School of Medicine, 8737 Beverly Blvd, Suite 203, Los Angeles, CA 90048, USA
    Curr Pain Headache Rep 8:364-8. 2004
    ..Of those patients with FM, 30% to 70% have concurrent IBS. Small intestinal bacterial overgrowth is associated with hyperalgesia and IBS-like complaints, is common in FM, and responds transiently to antimicrobial therapy...
  3. ncbi request reprint Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia
    Daniel J Wallace
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Semin Arthritis Rheum 37:256-9. 2008
    ....
  4. pmc Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    Daniel J Wallace
    David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, UCLA, Los Angeles, California, USA
    Ann Rheum Dis 73:183-90. 2014
    ..To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE)...
  5. pmc New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus
    Fang Fang Wang
    Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, 145 Middle Shan Dong Road, Shanghai 200001, China
    Arthritis Res Ther 14:R103. 2012
    ..In the present study, we investigated for the first time whether MIF correlated with steroid resistance in SLE and explored potential mechanisms of action...
  6. doi request reprint Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
    Daniel J Wallace
    Cedars Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA
    Rheumatology (Oxford) 52:1313-22. 2013
    ..To evaluate epratuzumab treatment in patients with moderately-to-severely active SLE in two international, randomized, controlled trials (ALLEVIATE-1 and -2) and an open-label extension study (SL0006)...
  7. doi request reprint Epratuzumab for systemic lupus erythematosus
    D J Wallace
    Cedars Sinai David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 22:400-5. 2013
    ..The agent clearly has anti-inflammatory activity and is a potentially useful agent in the management of autoimmune disorders...
  8. doi request reprint Ten developments in the use of biologicals for systemic lupus erythematosus
    Daniel J Wallace
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Curr Rheumatol Rep 15:337. 2013
    ..Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed...
  9. doi request reprint Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
    D J Wallace
    Cedars Sinai Medical Center David Geffen School of Medicine at UCLA, 8737 Beverly Blvd, W Hollywood, CA 90048, USA
    Lupus 22:144-54. 2013
    ..43 vs. 0.73. These data support the conclusion that belimumab in combination with standard SLE therapy was generally well tolerated in a predominantly autoantibody-positive population with active SLE...
  10. doi request reprint New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
    Daniel J Wallace
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Becker B 131, Los Angeles, CA 90048, USA
    Nat Rev Rheumatol 8:522-33. 2012
    ..Antimalarial agents have unique disease-modifying properties in SLE and newer iterations of this class of anti-inflammatory agents will have a profound effect upon the treatment of autoimmune disease...
  11. pmc The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study
    Matthew L Mundwiler
    North Suburban Rheumatologists, Des Plaines, IL 60016, USA
    Arthritis Res Ther 11:R94. 2009
    ..Similar analyses were performed for bone marrow edema, predicting a subsequent MRI erosion. Descriptive results of other lesions are reported...
  12. ncbi request reprint Is there a role for cytokine based therapies in fibromyalgia
    Daniel J Wallace
    Cedars Sinai David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Curr Pharm Des 12:17-22. 2006
    ..A review of the fibromyalgia literature and related studies suggest that IL-1, IL-6 and IL-8 are dysregulated in the syndrome. Therapies directed against these cytokines may be of potential importance in the management of fibromyalgia...
  13. ncbi request reprint What's new in the management of lupus since 2000?
    Daniel J Wallace
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    J Clin Rheumatol 12:307-13. 2006
  14. ncbi request reprint The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947)
    Daniel J Wallace
    Division of Rheumatology, Department of Medicine, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Semin Arthritis Rheum 32:208-30. 2003
    ..Reactive arthritis is often termed Reiter's syndrome, after Hans Reiter, who was incarcerated at Nuremberg...
  15. doi request reprint Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox
    D J Wallace
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 17:91-2. 2008
    ..Rheumatologists need to take the responsibility to ensure that their lupus patients have optimal primary care access which includes a working relationship with them...
  16. ncbi request reprint Quality-of-life, legal-financial, and disability issues in fibromyalgia
    D J Wallace
    Department of Medicine Division of Rheumatology, Cedars Sinai Medical Center UCLA School of Medicine, 8737 Beverly Building, Los Angeles, CA 90048, USA
    Curr Pain Headache Rep 5:313-9. 2001
    ..The principal legal issues associated with the syndrome are: Does fibromyalgia exist? Can it be caused by or flared by stress or trauma? Does disability apply to fibromyalgia and if so, how? These issues are critically reviewed...
  17. pmc Advances in drug therapy for systemic lupus erythematosus
    Daniel J Wallace
    Division of Rheumatology, Cedars Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA
    BMC Med 8:77. 2010
    ..This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted...
  18. ncbi request reprint LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
    D J Wallace
    Department of Medicine, Division of Rheumatology, Cedars Sinai UCLA School of Medicine, Los Angeles, USA
    Lupus 13:323-7. 2004
    ..LJP 394 is a promising induction and/or maintenance therapy for lupus patients with elevated anti-DNA and active disease...
  19. ncbi request reprint How Prosorba apheresis came to be used for rheumatoid arthritis: a personal historical perspective
    D J Wallace
    Cedars Sinai UCLA Medical Center, Los Angeles, California, USA
    Ther Apher 5:76-8. 2001
    ..In this article, I review how membrane methodologies evolved with regard to the management of the disorder through a focused review of rarely cited key references and personal experience...
  20. ncbi request reprint Apheresis for lupus erythematosus: state of the art
    D J Wallace
    Cedars Sinai UCLA School of Medicine, Los Angeles, CA 90048, USA
    Lupus 10:193-6. 2001
    ..It may be potentially useful in the antiphospholipid syndrome or mothers or children at risk for congenital heart block. Refinements in apheresis technology may expand the indications for PP...
  21. ncbi request reprint Clinical and pharmacological experience with LJP-394
    D J Wallace
    Clinical Professor of Medicine, Cedars Sinai University of California Los Angeles, 8737 Beverly Blvd, Suite 203, Los Angeles, CA 90048, USA
    Expert Opin Investig Drugs 10:111-7. 2001
    ..A definitive trial is in progress. LJP-394 appears to be free of serious adverse reactions. Though promising, the role of LJP-394 in patients with active, organ-threatening lupus is still not known...
  22. doi request reprint The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort
    I Moldovan
    Loma Linda University, California, USA
    Lupus 20:1285-92. 2011
    ..0001). Conclusion: Depression, and not disease activity, appears to have a major influence on quality of life in both Hispanic and Caucasian patients in this lupus cohort...
  23. pmc Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus
    B P Tsao
    University of California, Los Angeles, USA
    J Clin Invest 99:725-31. 1997
    ..01). We concluded that this candidate 1q41-q42 region probably contains a susceptibility gene(s) that confers risk for SLE in multiple ethnic groups...
  24. ncbi request reprint Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?
    M L Ishimori
    Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 16:436-43. 2007
    ..The therapeutic implications for separating PRES from stroke or cerebritis are important. We propose that PRES should be considered in the differential diagnosis in SLE patients with new-onset neurologic signs and symptoms...
  25. ncbi request reprint Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC
    M Linker-Israeli
    Department of Medicine, The Cedars Sinai Research Institute and UCLA, Los Angeles, California 90048, USA
    Clin Immunol 99:82-93. 2001
    ..These data suggest that 1,25 D(3) compounds can offer novel approaches to the clinical management of SLE...
  26. doi request reprint Review: Male systemic lupus erythematosus: a review of sex disparities in this disease
    L J Lu
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Lupus 19:119-29. 2010
    ..This review discusses these findings and sex disparities in SLE that appear to be especially noteworthy and pertinent to our understanding of male SLE...
  27. doi request reprint Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
    J D Posalski
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Lupus 18:516-21. 2009
    ..When evaluating organ system subsets separately, MMF improved disease activity in the first year, but had little effect in preventing new organ-specific flares, with most flares taking place in second and third year of treatment...
  28. pmc Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus
    Maureen McMahon
    David Geffen School of Medicine, UCLA Medical Center, University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 60:2428-37. 2009
    ..The aim of this study was to determine whether dysfunctional proinflammatory HDL (piHDL) is associated with subclinical atherosclerosis in SLE...
  29. ncbi request reprint Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis
    Maureen McMahon
    University of California at Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Arthritis Rheum 54:2541-9. 2006
    ..This study was undertaken to determine whether patients with SLE, who have chronic inflammation that causes oxidative damage, have more proinflammatory HDL and higher levels of ox-LDL, thus predisposing them to atherosclerosis...
  30. ncbi request reprint Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus
    Betty P Tsao
    Department of Medicine, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
    Arthritis Rheum 46:2928-36. 2002
    ....
  31. ncbi request reprint Familiality and co-occurrence of clinical features of systemic lupus erythematosus
    Betty P Tsao
    Division of Rheumatology, Department of Medicine, Rehabilitation Center, Room 32 59, University of California Los Angeles School of Medicine, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
    Arthritis Rheum 46:2678-85. 2002
    ..To evaluate familiality of 15 clinical and laboratory features in systemic lupus erythematosus (SLE)-affected sibpairs, and to estimate correlations with the age at SLE diagnosis in affected sibpairs and parent-offspring pairs...
  32. ncbi request reprint Systemic lupus erythematosus
    Daniel J Wallace
    Clinical Professor of Medicine, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Drugs Today (Barc) 38:259-63. 2002
    ....
  33. pmc Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
    Daniel E Furst
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:893-9. 2007
    ..To incorporate a new trial design to examine clinical response, cytokine expression and joint imaging in patients with rheumatoid arthritis (RA) switching from etanercept to infliximab treatment...
  34. pmc Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus
    Elizabeth R Volkmann
    David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1670, USA
    Arthritis Care Res (Hoboken) 62:258-65. 2010
    ..To investigate the association between physical activity, functional activity of high-density lipoprotein (HDL), and subclinical cardiovascular disease in patients with systemic lupus erythematosus (SLE)...
  35. ncbi request reprint Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo
    V Strand
    Division of Immunology, Stanford University, Palo Alto, CA, USA
    Lupus 12:677-86. 2003
    ..Differences between treatment groups in RE and SF domains are clinically important and were replicated irrespective of the protocol population analysed...
  36. ncbi request reprint Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study
    D J Wallace
    Department of Medicine/Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA
    Rheumatology (Oxford) 40:743-9. 2001
    ..Because IL-8 promotes sympathetic pain and IL-6 induces hyperalgesia, fatigue and depression, it is hypothesized that they may play a role in modulating FM symptoms...
  37. ncbi request reprint Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study
    C F Remer
    Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
    Lupus 10:480-3. 2001
    ..Blood pressure was unchanged. Leflunomide was efficacious and safe in this cohort of SLE patients after 2-3 months of therapy. Placebo-controlled trials of longer duration are indicated...
  38. ncbi request reprint Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD28(lo) T cells in patients with systemic lupus erythematosus
    M Honda
    Department of Medicine, Cedars-Sinai Research Institute and the University of California at Los Angeles, Los Angeles, CA 90048, USA
    Clin Immunol 99:211-221. 2001
    ..5 TAU in CD8+CD28(hi) cells and 0.3 TAU in bulk PBMC; P = 0.05]. These T cell anomalies could be due to chronic in vivo stimulation of the immune system and may contribute to the immune dysregulation found in SLE...
  39. pmc Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus
    Hui Wu
    Division of Rheumatology, University of California Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 104:3961-6. 2007
    ..Our findings reveal that CR2 is a likely susceptibility gene for human lupus at 1q32.2, extending previous studies suggesting that CR2 participates in the pathogenesis of systemic lupus erythematosus...
  40. ncbi request reprint Novel therapies in the treatment of systemic lupus erythematosus
    C R Dequet
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Opin Investig Drugs 2:1045-53. 2001
    ..In our opinion, leflunomide and LJP-394 are the most promising therapies currently, under study...
  41. doi request reprint Depression predicts self-reported disease activity in systemic lupus erythematosus
    F N Carr
    California School of Professional Psychology, Alliant International University, Los Angeles, California, USA
    Lupus 20:80-4. 2011
    ..Longitudinally, depression alone predicted self-reported disease activity. These data suggest that depression may play a significant role in the health status of SLE patients and serve as an important target for clinical intervention...
  42. ncbi request reprint The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literature
    J Spiegel
    Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 16:52-5. 2007
    ..This report represents the lowest birth weight pregnancy survival in a lupus patient and the first case of a survival in the second trimester with preeclampsia and HELLP syndrome...
  43. doi request reprint Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity
    A Ippolito
    Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
    Lupus 20:250-5. 2011
    ..Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials...
  44. doi request reprint High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus
    N Firooz
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Lupus 20:588-97. 2011
    ..Elevated hsCRP levels can be used as a predictor of active infection in SLE patients with a high specificity. We review the relationship between IL-6 and hsCRP production in lupus patients...
  45. ncbi request reprint Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families
    R Shai
    Division of Rheumatology, Department of Medicine, University of Southern California School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
    Hum Mol Genet 8:639-44. 1999
    ....
  46. doi request reprint Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus
    J G Hanly
    Department of Medicine, Division of Rheumatology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Ann Rheum Dis 70:1726-32. 2011
    ..This study examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrolment predicted subsequent neuropsychiatric events...
  47. ncbi request reprint Gastrointestinal manifestations of systemic lupus erythematosus
    D S Hallegua
    Division of Rheumatology, Cedars Sinai Medical Center UCLA School of Medicine Los Angeles, California, USA
    Curr Opin Rheumatol 12:379-85. 2000
    ..In patients with abdominal pain and active SLE, it is critical to diagnose vasculitis or thrombosis with appropriate scanning and institute early immunosuppressive or surgical treatment...
  48. pmc PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus
    B P Tsao
    Division of Rheumatology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1670
    J Clin Invest 103:1135-40. 1999
    ..004). Similar TDT analyses of TGFB2 and HLX1 polymorphisms yielded no evidence for association with SLE. These results suggest that PARP may be (or is close to) the susceptibility gene within the chromosome 1q41-q42 region linked to SLE...
  49. pmc A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
    Daniel J Wallace
    Cedars Sinai Medical Center, University of California, Los Angeles, USA
    Arthritis Rheum 61:1168-78. 2009
    ..To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE)...
  50. ncbi request reprint The management of fibromyalgia-associated syndromes
    David S Silver
    Division of Rheumatology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Rheum Dis Clin North Am 28:405-17. 2002
    ..The successful treatment of fibromyalgia-associated syndromes improves the symptoms, quality of life, and prognosis of fibromyalgia...
  51. ncbi request reprint Development and validation of a preference weight multiattribute health outcome measure for rheumatoid arthritis
    Chiun Fang Chiou
    Amgen, Inc, Thousand Oaks, California, USA
    J Rheumatol 33:2409-11. 2006
    ..To develop and validate multiattribute measures for patients with rheumatoid arthritis (RA) to report health states and estimate preference weights...
  52. ncbi request reprint Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Rheum 54:607-12. 2006
    ..This study investigated whether risk genotypes for folate-dependent enzymes are associated with the toxicity of MTX in patients with rheumatoid arthritis (RA)...
  53. pmc Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome
    Cai Sheng Lu
    University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 52:4018-27. 2005
    ..To test the hypotheses that some plasmin-reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of the tPA-reactive aCL may inhibit tPA activity...
  54. ncbi request reprint Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease
    Hui Wu
    David Geffen School of Medicine, University of California, Los Angeles, 90095, USA
    Arthritis Rheum 52:2396-402. 2005
    ..We performed family-based association studies of this polymorphism in 4 independent cohorts containing SLE patients and their parents and/or other family members...
  55. ncbi request reprint Eligibility, utilization, and costs in a California Medicaid lupus population
    Michael B Nichol
    University of Southern California, Los Angeles, California 90033, USA
    Arthritis Rheum 51:996-1003. 2004
    ..To investigate whether ethnicity was associated with differences in Medicaid eligibility, health care utilization, and direct medical costs in a systemic lupus erythematosus (SLE) population...
  56. doi request reprint Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus
    Anca D Askanase
    Department of Medicine, Hospital for Joint Diseases, Division of Rheumatology, New York University School of Medicine, 560 First Avenue, TCH 407, New York, NY 10016, USA
    J Rheumatol 36:89-95. 2009
    ..Our objective was to evaluate whether drug escalation based on metabolite levels improves efficacy and maintains safety in patients with systemic lupus erythematosus (SLE)...
  57. ncbi request reprint Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE
    S A Lander
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Lupus 11:340-7. 2002
    ..These results suggest that patients with SLE can be safely and effectively treated with celecoxib; however, further studies are needed to assess the effectiveness and safety of all NSAIDs in SLE...
  58. ncbi request reprint Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus
    Arash A Horizon
    Cedars Sinai UCLA School of Medicine, Los Angeles, CA 90048, USA
    Expert Opin Drug Saf 3:273-8. 2004
    ..Nevertheless, NSAIDs can safely be prescribed to most lupus patients provided that their administration is re-evaluated on a regular basis and the patient is closely monitored...
  59. ncbi request reprint Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
    ..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
  60. ncbi request reprint Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome
    Ernest R Vina
    Internal Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Semin Arthritis Rheum 35:175-84. 2005
    ..To identify clinical characteristics, laboratory features, approaches to management, and predictors of outcome of chronic inflammatory demyelinating polyneuropathy (CIDP) in patients with systemic lupus erythematosus (SLE)...
  61. doi request reprint Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus
    Catherine B Driver
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Rheum 59:332-7. 2008
    ....
  62. doi request reprint Lupus registries: evolution and challenges
    Liang Jing Lu
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Semin Arthritis Rheum 39:224-45. 2010
    ....
  63. ncbi request reprint Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
    Christian E Antoni
    Clinical Immunology, Schering Plough Corporation, Kenilworth, New Jersey 07033 0530, USA
    J Rheumatol 35:869-76. 2008
    ..To investigate longterm efficacy/safety of infliximab over 2 years in patients with active psoriatic arthritis (PsA)...
  64. ncbi request reprint Measuring preference weights for American college of rheumatology response criteria for patients with rheumatoid arthritis
    Chiun Fang Chiou
    Cerner Health Insights, Beverly Hills, California 90212, USA
    J Rheumatol 32:2326-9. 2005
    ..To estimate weights for health states comprising American College of Rheumatology (ACR) response and different levels of adverse events associated with rheumatoid arthritis (RA) treatments...
  65. ncbi request reprint Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation
    Richard S Panush
    Arthritis Rheum 56:693-4. 2007
  66. doi request reprint Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial
    Mario H Cardiel
    Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
    Arthritis Rheum 58:2470-80. 2008
    ....
  67. ncbi request reprint The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious
    Daniel J Wallace
    J Rheumatol 30:1897-9. 2003
  68. ncbi request reprint New therapies in systemic lupus erythematosus
    Marilyn A Solsky
    Best Pract Res Clin Rheumatol 16:293-312. 2002
    ..A handful of biologicals have been studied in clinical trials. After two decades without new options for lupus patients practitioners now have a full menu of improved therapeutic options...
  69. ncbi request reprint Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    Christian E Antoni
    Friedrich Alexander University, Erlangen Nuremberg, Germany
    Arthritis Rheum 52:1227-36. 2005
    ..To investigate the efficacy and tolerability of infliximab therapy for the articular and dermatologic manifestations of active psoriatic arthritis (PsA)...
  70. ncbi request reprint New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective
    Daniel J Wallace
    Pol Arch Med Wewn 118:402-3. 2008
  71. doi request reprint Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response
    Michelle Petri
    Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Arthritis Rheum 58:1789-95. 2008
    ..To assess the degree to which physicians agree with each other and with ratings obtained with 3 existing responder indices, in rating the response to treatment of lupus nephritis...
  72. doi request reprint Additional components to measuring fatigue in patients with systemic lupus erythematosus: comment on the article by the Ad Hoc Committee on systemic lupus erythematosus response criteria for fatigue
    Daniel J Wallace
    Arthritis Rheum 59:1049; author reply 1049-50. 2008
  73. ncbi request reprint Pyridostigmine for fibromyalgia: comment on the article by Paiva and a historical vignette
    Daniel J Wallace
    Arthritis Rheum 48:277-8. 2003
  74. ncbi request reprint Whiplash: a case of regretting being responsible for naming a condition
    Daniel J Wallace
    J Clin Rheumatol 11:61. 2005
  75. doi request reprint Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index
    Michelle Petri
    Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Arthritis Rheum 58:1784-8. 2008
    ..To develop a measure of renal activity in systemic lupus erythematosus and use it to develop a renal response index...
  76. ncbi request reprint Rapid prevention of vertebral fractures associated with osteoporosis
    Daniel J Wallace
    Cedars Sinai Medical Center David Geffen School of Medicine at UCLA, Los Angeles, Calif 90047, USA
    Orthopedics 28:291-8. 2005
    ..Rapid reduction in fracture risk is achievable with the potent therapeutic agents available...
  77. ncbi request reprint To fibromyalgia nihilists: stop pontificating and test your hypothesis
    Daniel J Wallace
    J Rheumatol 31:632. 2004